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Human hyaluronidase-2 is localized intracellularly in articular
chondrocytes and other cultured cell lines*
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SocietyIn a Letter to the Editor by Miller et al., arguments are made
concerning the localization of HYAL-2 in chondrocytes and
other cells. The authors present historical as well as new
evidence that the hyaluronidase, HYAL-2 is present on
the surface of cells, in contradiction to the recent work of
Chow et al.1 The Letter also provides commentary as to
why the results published by Chow et al. are inconclusive
and thus, concludes that their view is the only correct pos-
sibility. Unfortunately the arguments in the Letter to the Ed-
itor are incorrect or speculative in nature and the data
presented is, itself, inconclusive.
The primary data supplied by the authors of the Letter to the
Editor show that a human chondrosarcoma cell line, CH1.2
exhibits the capacity to support the entry of jaagsiekte
sheep retrovirus, a process dependent on the expression
of cell surface, glycosyl phophatidylinositol (GPI)-linked
HYAL-2. Even though this cell line expresses some pheno-
typic properties of a differentiated human chondrocyte, it
cannot be considered a chondrocyte, nor should it be la-
beled as one. Numerous phenotypic alterations have oc-
curred in this cell line and one cannot be sure whether
any of these have altered the post-translational processing
of the HYAL-2. The original CH1 line was derived from an
aggressive human chondrosarcoma2. The line exhibited
a doubling time of 2 days and expressed abundant mRNA
for transforming growth factor-beta. Although the line syn-
thesizes aggrecan mRNA, multiple splicing isoforms are ex-
presseddisoforms that are not exhibited in normal cartilage
or benign cartilaginous tumors3. The study by Chow et al.
utilized primary cultures of human articular chondrocytes
derived from normal donors with no known history of dis-
ease. While no in vitro model system is perfect, the use of
such primary cells represents the best approach to address
whether HYAL-2 is present in chondrocytes under physio-
logical conditions.
The Letter by Miller et al. also comments on the work of
Chow et al. concerning the various epitope-tagged con-
structs. The authors make a valid point that by constructing
HYAL-2 with a carboxy-terminal V5 tag, this tagged
sequence would be removed upon transfer to a GPI link-
age, assuming that is, that the transfer occurs in these cells.
Nonetheless, Chow et al. demonstrate V5-tagged protein
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HYAL-2) and further, demonstrate that the expression of
these bands is blocked with HYAL-2 antisense morpholino
oligonucleotides. So, even granting that a transfer to GPI
occurs to a fraction of the HYAL-2 synthesized, the
presence of HYAL-2 protein with a V5-tag still attached im-
plies the existence of second pool of HYAL-2 that is not GPI
linked. A similar argument is made for constructs with a myc
epitope tag added to the amino-terminal of HYAL-2. The
contention by Miller et al. is that the myc tag would be re-
moved along with the signal leader peptide following pas-
sage into the endoplasmic reticulum. This however is
incorrect. The myc-tagged HYAL-2 was cloned into a pSec-
Taq2 that contains not only a start codon but also an Ig
kappa signal peptide leader sequence. It is this signal
peptide that is cleaved by the signal peptidase leaving the
myc tag intact and still attached to the HYAL-2. It is for
this reason that Chow et al. again obtained full-length myc-
tagged protein at 55 kDa. In a preliminary experiment, the
Chow et al. authors incorporated the myc tag into the
amino-terminal of a HYAL-2 devoid of its native leader
sequence. Again, using the pSecTaq2 vector leader
sequence to direct insertion of the protein into the endoplas-
mic reticulum, a full-length myc-tagged HYAL-2 protein was
obtained. Additionally, as with the previous work, this
myc-tagged HYAL-2 could only be detected intracellularly
as it required permeabilization of the cell membrane for
detection.
A second criticism in the Letter by Miller et al. is that the
peptide-speciﬁc antibodies generated by Chow et al. are not
recognizing native protein. While this is always a possibility,
there is no direct evidence to support the suggestion. Such
statements could be made concerning the use of all peptide-
speciﬁc polyclonal antibodies. Nonetheless, Chow et al.
did demonstrate in Fig. 8(B) of their manuscript that an
increase in HYAL-2 protein, detected by the antibody by
Western blotting, is matched by an increase in hyaluron-
idase activity (at the same molecular size) as measured
using hyaluronan zymography. Thus, while it is still possi-
ble that antigen and the hyaluronidase activity represent
separate pools of HYAL-2, the most straightforward
explanation is that the antibody is recognizing the
native functional enzyme. Further, looking at the immuno-
ﬂuorescence localization provided by Chow et al., it is un-
clear why there would be such a deﬁned localization of
the antigen to vesicles throughout the cytoplasm if the an-
tibody were recognizing denatured protein. The work by
Miller et al. in the Letter only supports the contention
that there is HYAL-2 present at the cell surface of this
chondrosarcoma cell line. There are no data given as to312
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HYAL-2, such as within lysosomes. It is also not clear
in the studies presented in the Letter as to how much
HYAL-2 is necessary to support viral entry. Is it possible
that HYAL-2 is present in a GPI linkage but below the
level detected by immunoﬂuorescence?
Along these same lines, the Letter by Miller et al. dis-
cusses another contradiction concerning the susceptibility
of HEK293 and HeLa cells to jaagsiekte sheep retrovirus.
In the Letter, Miller et al. state that HeLa cells are not
susceptible to infection by virus. However, Chow et al.
demonstrate that HYAL-2 mRNA and full-length HYAL-2
protein are present in both HEK293 and HeLa cells. Miller
et al. speculate that perhaps some defect in the endoge-
nous HYAL-2 prevents this protein from being expressed
in HeLa cells. Again, a simpler explanation is that the
HYAL-2 in both of these cell lines is primarily expressed
intracellularly and that in some cells, a fraction of the total
can also be expressed extracellularly after transfer to
a GPI linkage.
The issues presented in the Letter also sidestep the ma-
jor question that was being addressed by Chow et al. The
real issue is not whether there is a sub-threshold level of
HYAL-2 present at the surface of cells that can support
the entry of jaagsiekte sheep retrovirus. The major question
is whether there is hyaluronidase activity present at the cell
surface that could participate in the catabolism of hyalur-
onan. It has been argued that if HYAL-2 were present on
the surface of cells such as chondrocytes, at high enough
levels, certain environmental conditions might exist under
which the enzymatic processing of hyaluronan could take
place extracellularly. Both HYAL-1 and HYAL-2 have well-
documented pH 3.7 optima for their hyaluronidase activity.
Even Dr Miller in his previous studies4 could not detect
any hyaluronidase activity in lysates or conditioned media
of NIH 3T3 or HeLa cells at pH 7.5. Nonetheless, it is some-
times argued that perhaps some unique lipid environment of
the plasma membrane may alter this pH requirement allow-
ing HYAL-2 to be active at higher pH conditions. We
attempted to address this issue by testing the capacity of
chondrocytes to degrade their hyaluronan-rich pericellular
matrix under reduced pH conditions. We have shown previ-
ously that the pericellular matrices observed on chondro-
cytes in vitro represent primarily aggrecan attached to a
limited scaffolding of hyaluronan5e7. These matrices remain
tightly bound to the chondrocyte cell surface [Fig. 1(A)]
but are highly sensitive to even dilute concentrations ofStreptomyces or testicular hyaluronidase [Fig. 1(B)]. Using
this model, the pH of the culture medium of separate cul-
tures of bovine articular chondrocytes was lowered by incre-
ments of 0.5 units. Below pH 5.0 the cells lift off the dish and
could not be analyzed (data not shown). However, as
shown in Fig. 1(C), chondrocytes incubated at pH 5.5
exhibit no change in the size of the cell-associated matrix,
even after 6 h under these conditions. It is unlikely that
chondrocytes in cartilage ever reach this pH. However,
this demonstrates that if the cellular environment did reach
this pH, there still would be no effect on the matrix structure
or content of extracellular hyaluronan. This ﬁgure was not
included in the ﬁnal version of the manuscript by Chow
et al., published in Osteoarthritis and Cartilage. In retro-
spect, it would have been useful to include these data. In
the discussion of this ﬁgure we argued that perhaps our
analytical approaches were not sensitive enough or appro-
priate to detect minute levels of membrane-associated
HYAL-2 or, perhaps there was a different hyaluronidase be-
sides HYAL-2 was present on the surface of these cells.
The functional assay shown herein in Fig. 1 suggests that
even if HYAL-2 or some other hyaluronidase were present,
it is unlikely to be a major contributor to the physiological
turnover of hyaluronan.
In summary, the argumentsmade byMiller and colleagues
in their Letter to the Editor are in some cases incorrect, in
other cases speculative and the data they present, inconclu-
sive. The myc tag was not cleaved from the amino-terminal
of the HYAL-2 upon insertion into the endoplasmic reticulum.
Thus, the fact that the myc epitope was intracellularly-local-
ized in the study by Chow et al. suggests that the HYAL-2 is
either not GPI-linked or that a portion of the HYAL-2 is trans-
ferred to aGPI linkages but is not exported to the cell surface.
Given that full-length HYAL-2 was obtained containing an
epitope tag on either the carboxy- or amino-terminus, sug-
gests that a signiﬁcant pool of HYAL-2 exists within the cell
that has not been enzymatically processed and transferred
to a GPI linkage. That the polyclonal antibody staining
matches the immunostaining of the recombinant HYAL-2
with an myc epitope tag, suggests that the native endoge-
nous HYAL-2 expressed by chondrocytes is also present
predominately as an intracellular protein.
In conclusion, there will always be possible counter ar-
guments to all published studies. However, this is proba-
bly best evaluated by experiment rather than speculation.
Nonetheless, future studies may more conclusively dem-
onstrate that a level of HYAL-2 exists on the surface ofFig. 1. Endogenous pericellular matrices are sensitive to Streptomyces hyaluronidase but stable at pH 5.5. Fixed erythrocytes were applied as
a uniform-sized particle suspension to low density cultures of bovine articular chondrocytes to reveal the pericellular matrix surrounding living
cells as described previously5e7. Panel A: pH 7.4 conditions; panel B: pH 7.4 in the presence of 2 units/ml Streptomyces hyaluronidase; and
panel C: pH 5.5 conditions.
1314 Letter to the Editormost cells including chondrocytes. However, it is more
likely that the membrane-bound HYAL-2 levels will vary
from one cell type to another. In some cells this level
will be undetectable by standard immunological ap-
proaches and some will be so low that they will not sup-
port the entry of HYAL-2 dependent retroviruses. But in
all cells HYAL-2 and HYAL-1 will always be predominate
intracellularly, contributing as low pH optima hydrolases
to the intracellular degradation of hyaluronan.
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